The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S.

The Trump administration's aid freeze affects HIV treatment access. Find out how organizations are coping with the directive.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future ...

PreP is extremely effective at preventing HIV infection. According to the Centers for Disease Control and Prevention, PReP drugs like Truvada Descovy can reduce the risk of getting HIV by 99 percent ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the bioscience giant for allegedly using joint research to develop an ...

A new case before the Supreme Court targeting preventive coverage mandates under Obamacare gives President-elect Donald Trump a chance to undermine one of the most controversial aspects of the healthc ...

two decades ago to discover whether Truvada—which was approved in 2004 to treat HIV—could also prevent the infection. “Today’s settlement ends this litigation and this final resolution ...

The US government alleged that Gilead had inadequately compensated the CDC for its pivotal research on Truvada's preventative uses, supposedly sidestepping pertinent patents. With the settlement now ...

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...